MPAM
RGNX icon

Monarch Partners Asset Management’s Regenxbio RGNX Stock Holding History

Monarch Partners Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.63M Sell
72,064
-27,456
-28% -$621K 0.48% 104
2022
Q3 		$2.63M Buy
+99,520
New +$2.95M 0.79% 53

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Monarch Partners Asset Management's RGNX Position: Q4 2022 in Review

Monarch Partners Asset Management reduced its Regenxbio (RGNX) stake by 28% in Q4 2022, selling an estimated $621K and leaving 72,064 shares worth $1.63M. The position accounts for 0.48% of the portfolio, ranked #104.

Monarch Partners Asset Management first reported a position in RGNX in Q3 2022 and has held it in 2 quarters since. The position peaked at $2.63M in Q3 2022. 182 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Monarch Partners Asset Management held 72,064 shares of Regenxbio worth $1.63M as of Q4 2022.
  • Monarch Partners Asset Management sold 27,456 Regenxbio shares in Q4 2022, an estimated $621K.
  • Regenxbio made up 0.48% of Monarch Partners Asset Management's portfolio in Q4 2022, its #104 holding.
  • Monarch Partners Asset Management first reported a position in Regenxbio in Q3 2022 and has held it in 2 quarters since.
  • Monarch Partners Asset Management's Regenxbio position peaked at $2.63M in Q3 2022.
  • 182 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.